Jingcheng Lyu1,2,#, Ruiyu Yue1,2,#, Yichen Zhu1,2, Ye Tian1,2,*, Xinyi Hu1,2,*
Canadian Journal of Urology, Vol.32, No.5, pp. 411-422, 2025, DOI:10.32604/cju.2025.066758
- 30 October 2025
Abstract Objective: Urothelial carcinoma (UC) remains a prevalent malignancy with high recurrence and chemoresistance rates despite gemcitabine-cisplatin (GC) chemotherapy. The study aimed to identify clinical risk factors for chemoresistance in advanced UC patients and develop a predictive model. Method: A retrospective analysis was conducted on 375 UC patients who received postoperative GC chemotherapy between 2013 and 2024. Patients were categorized into chemotherapy-resistant (CR, n = 91) and non-chemotherapy resistant (NCR, n = 284) groups based on tumor progression. Clinical, pathological, and laboratory variables were compared using t-tests and chi-square tests. Kaplan-Meier assessed overall survival (OS), and binary More >